A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study) - A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study)

Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University0 sites30 target enrollmentAugust 8, 2014

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Not specified
Sponsor: Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University
Enrollment: 30
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

August 8, 2014

End Date

November 16, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University

•1\) Multiple primary cancers with disease\-free period less than 5\-years, except carcinoma in situ or intra mucosal disease cured by local therapy 2\) Past history of severe hypersensitivity to drug 3\) Active incection 4\) Fever more than 38 degree 5\) Central nervous system metastasis or carcinomatous meningitis 6\) Massive cardiac effusion, pleural effusion or ascites 7\) Peripheral sensory neuropathy : grade 2 or above (CTCAE v4\.0\) 8\) Chronic daily treatment with oral or intravenous corticosteroids 9\) Unstable angina or past history of myocardinal infraction in 6 months 10\) Evidence of any other serious disease ; renal failure, hepatic failure, interstinal pneumonitis or lung fibrosis 11\) Pregnant, lactating female, female of childbearing potential or male without contracepcion intention 12\) Psychiatric disease that is inapprocpriate for entry into this study 13\) Any patients judged by the investigator to be unfit to participate in the study